Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cul

Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0377/2023